ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data…
LONDON, Oct. 20, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed…
Image by Contemporary Care NAPLES, Fla., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Contemporary Care today announced the availability of Transcranial…
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase…
October 02, 2025 10:00 ET | Source: Cirrus Therapeutics, Inc. Cirrus’ lead program is a novel AAV gene therapy designed…
September 26, 2025 New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with…
KOLKATA, India, Sept. 25, 2025 /PRNewswire/ -- In a major milestone for cancer care in Eastern India, doctors at Apollo…
89bio’s pegozafermin allows for a potentially best-in-disease treatment for moderate to severe Metabolic Dysfunction-Associated Steatohepatitis (MASH), one of the most…
September 09, 2025 13:19 ET | Source: Booking Health Langenfeld, Germany, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Booking Health, a…
This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been approved based on an objective…